These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33408473)

  • 21. Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study.
    Opinc A; Sarnik J; Brzezińska O; Makowski M; Lewandowska-Polak A; Makowska J
    Rheumatol Int; 2020 Jul; 40(7):1133-1141. PubMed ID: 32222805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary Production of Soluble ST2 in Heart Failure.
    Pascual-Figal DA; Pérez-Martínez MT; Asensio-Lopez MC; Sanchez-Más J; García-García ME; Martinez CM; Lencina M; Jara R; Januzzi JL; Lax A
    Circ Heart Fail; 2018 Dec; 11(12):e005488. PubMed ID: 30562096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure.
    Jiang SW; Wang P; Xiang XG; Mo RD; Lin LY; Bao SS; Lu J; Xie Q
    Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):181-188. PubMed ID: 28381383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
    Pusceddu I; Dieplinger B; Mueller T
    Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
    Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of an amplified luminescent proximity homogeneous immunoassay kit for detecting human hepatitis B virus e antibody].
    Ma Q; He A; Dong ZN; Liu TC; Zou LP; Lin GF; Li M; Wu YS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):810-2. PubMed ID: 21602130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble ST2, a modulator of the inflammatory response, in preterm and term labor.
    Stampalija T; Chaiworapongsa T; Romero R; Tarca AL; Bhatti G; Chiang PJ; Than NG; Ferrazzi E; Hassan SS; Yeo L
    J Matern Fetal Neonatal Med; 2014 Jan; 27(2):111-21. PubMed ID: 23688338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Competitive light-initiated chemiluminescent assay: using 5-α-dihydrotestosterone-BSA as competitive antigen for quantitation of total testosterone in human sera.
    Cui Y; She T; Zhao H; Li J; Li L; Gao W; Li H
    Anal Bioanal Chem; 2019 Jan; 411(3):745-754. PubMed ID: 30478516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
    Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
    Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment of a sandwich light-initiated chemiluminescence assay with double antigen for detecting human cytomegalovirus IgG antibody.
    Liu Z; Yu Y; Liu H; Chen X; Li L; Huang L; Li H
    J Med Virol; 2021 Aug; 93(8):5025-5032. PubMed ID: 33634873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between serum soluble suppression of tumorigenicity (ST) 2 and global longitudinal strain in early onset preeclampsia.
    Prameswari HS; Effendi CA; Khalid AF; Irianti S; Fatati I; Akbar MR
    BMC Cardiovasc Disord; 2024 Jan; 24(1):53. PubMed ID: 38229046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
    Zhang Q; Hu M; Ma S
    J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sandwich-type homogeneous chemiluminescence immunoassay based on nanoparticle toward detection of Aspergillus galactomannan antigen.
    Guo Y; Li J
    Talanta; 2022 Jun; 243():123392. PubMed ID: 35313134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ST2 Signaling in the Tumor Microenvironment.
    Chang CP; Hu MH; Hsiao YP; Wang YC
    Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.
    Yamada S; Shimizu M; Kuroda M; Inoue N; Sugimoto N; Yachie A
    Clin Exp Nephrol; 2019 Apr; 23(4):544-550. PubMed ID: 30467800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ST2 elevation in heart failure, predictive of a high early mortality.
    Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
    Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
    Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
    Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble ST2 is associated with increased carotid intima-media thickness in patients with type 2 diabetes mellitus: A case-control study.
    Hu X; Zhang H; Song Y; Yang Q; Zhuang L; Jin G; Zhang S; Sun W; Shi Z
    Medicine (Baltimore); 2020 Jan; 99(5):e18940. PubMed ID: 32000412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.